Eli Lilly’s New Once-Daily Weight-Loss Pill ‘Foundeo’ Wins FDA Approval, Offering Greater Convenience Than Injectables
New York, USA – Federal regulators have approved Eli Lilly’s new oral weight-loss medication, Foundeo, making it the second daily pill available in the United States for treating obesity and related conditions.
Unlike the first GLP-1 pill (a tablet version of Wegovy approved in December), Foundeo can be taken at any time of day without restrictions on food or water intake.
Eli Lilly designed the medication to be as simple as taking any other daily pill, addressing one of the biggest complaints about existing injectable GLP-1 treatments.
In clinical trials, participants with obesity who took Foundeo lost an average of 27 pounds.
The pill also showed promising results for people switching from injectable versions, with many maintaining their weight loss. Users and doctors repor...